Colitis ulcerativa para no gastroenterólogos

Autores/as

  • Nicolás Zuluaga Arbeláez Universidad CES https://orcid.org/0000-0002-7648-3462
  • Elsy Cristina Sierra Vargas Universidad CES
  • Juan Camilo Díaz Coronado Universidad CES
  • Luis Gonzalo Guevara Casallas Universidad CES

Palabras clave:

Colitis ulcerosa, Enfermedades intestinales, Diagnóstico, Terapéutica

Resumen

La colitis ulcerativa es una enfermedad intestinal inflamatoria crónica, de
etiología idiopática y fisiopatología multifactorial, caracterizada por la infla
mación de la mucosa rectal, con extensión proximal, continua y simétrica a través del colon. Su diagnóstico se establece a partir de los hallazgos clínicos, endoscópicos e histológicos. La meta terapéutica es lograr la remisión clínica y  endoscópica, reducir el riesgo de colectomía, cáncer colorrectal y
mejorar la calidad de vida de los pacientes. Se realizó una búsqueda de artículos científicos y se exponen los aspectos más relevantes y actualizados
sobre la enfermedad; con el objetivo de proporcionar elementos para su
abordaje diagnóstico y terapéutico.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Nicolás Zuluaga Arbeláez, Universidad CES

Médico, Residente Medicina Interna Universidad CES

Elsy Cristina Sierra Vargas, Universidad CES

[1] Médica, Especialista en Medicina Interna. Universidad de Antioquia.

Juan Camilo Díaz Coronado, Universidad CES

Médico, Especialista en Medicina Interna, Magister en epidemiología. Universidad CES

Luis Gonzalo Guevara Casallas, Universidad CES

Médico, Especialista en Medicina Interna y  Gastroenterología

Citas

Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Elsevier health sciences. 10th ed.2018; pp 2030-2031

Kobayashi T, Siegmund B, Le Berre C, Wei S, Ferrante M, Shen B et al. Ulcerative colitis. Nature Reviews Disease Primers. 2020;6(1).

Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of Gastroenterology. 2018;53(3):305-353.

Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019 Dec;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004. Epub 2019 Mar 2. PMID: 30837080.

Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, De Santos CR, et al. Patients’ perceptions of the impact of ulcerative colitis on social and professional life: Results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence 2018;12:1815–23.

Lichtenstein GR, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, et al. Lifetime economic burden of Crohn’s Disease and Ulcerative Colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18 (4):889-897.e10.

Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019 Dec 1;2019:7247238. doi: 10.1155/2019/7247238. PMID: 31886308; PMCID: PMC6914932.

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis.The Lancet 2017 p. 1756–70.

Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107 (1):3–11.

Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011;7 (4):235–41.

Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am. 1989;18 (1):73–82.

Desai J, Elnaggar M, Hanfy A, Doshi R. Toxic Megacolon: Background, pathophysiology, management challenges and solutions. 2020.

Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19 (4):789–99.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114 (3):384–413.

Bentley E, Jenkins D, Campbell F, Warren B. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J Clin Pathol 2002;55 (12):955–60.

Sherwood R, Walsham N. Fecal calprotectin in inflammatory bowel disease. Clinical and Experimental Gastroenterology. 2016:21.

Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18 (10):1894–9.

Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. J Crohn’s Colitis 2013;7 (7):556–85.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant R V., et al. Selecting Therapeutic targets in inflammatory bowel disease (STRIDE): Determining Therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110 (9):1324–38.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010; (1).

Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. Topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: Systematic review and meta-analysis. Am J Gastroenterol; 2012 p. 167–76.

Kane S V., Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96 (10):2929–33.

Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology 2015;148 (5):1035-1058.e3.

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Available from: https://pubmed.ncbi.nlm.nih.gov/31562236/

Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032. Erratum in: J Crohns Colitis. 2017 Dec 4;11(12):1510.

Astó E, Méndez I, Audivert S, Farran-Codina A, Espadaler J. The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. Nutrients. 2019 Jan 30;11(2):293. doi: 10.3390/nu11020293.

Publicado

2020-12-09

Cómo citar

Zuluaga Arbeláez, N., Sierra Vargas, E. C., Díaz Coronado, J. C., & Guevara Casallas, L. G. (2020). Colitis ulcerativa para no gastroenterólogos. CES Medicina, 34(3), 188-197. Recuperado a partir de https://revistas.ces.edu.co/index.php/medicina/article/view/5725

Número

Sección

Revisión de tema